StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) stock

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.36−0.04 (-8.94%)

Close on Nov 17, 2026Market cap $87.79MP/E –Yield –

Outlook Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Outlook Therapeutics's total debt was $967.06M at Jun 30, 2020. For fiscal 2019 it was $1.08B, up 652426.3% from the year before. The highest annual figure on record is $1.08B in fiscal 2019.

Annual total debt

PeriodPeriod endValueChange
FY2019Sep 30, 2019$1.08B+652426.3%
FY2018Sep 30, 2018$164.97K-19.0%
FY2017Sep 30, 2017$203.71K-92.8%
FY2016Sep 30, 2016$2.82M-23.1%
FY2015Sep 30, 2015$3.67M–

Quarterly total debt

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2020CQ2 2020Jun 30, 2020$967.06M+673862.3%
Q4 FY2019CQ3 2019Sep 30, 2019$1.08B+652426.3%
Q3 FY2019CQ2 2019Jun 30, 2019$1.11M+460.6%
Q2 FY2019CQ1 2019Mar 31, 2019$1.13M+388.9%
Q1 FY2019CQ4 2018Dec 31, 2018$143.49K-45.3%
Q4 FY2018CQ3 2018Sep 30, 2018$164.97K-19.0%
Q3 FY2018CQ2 2018Jun 30, 2018$198.28K-8.1%
Q2 FY2018CQ1 2018Mar 31, 2018$230.69K-8.8%
Q1 FY2018CQ4 2017Dec 31, 2017$262.25K-13.1%
Q4 FY2017CQ3 2017Sep 30, 2017$203.71K-92.8%
Q3 FY2017CQ2 2017Jun 30, 2017$215.76K-71.3%
Q2 FY2017CQ1 2017Mar 31, 2017$253.07K-66.7%
Q1 FY2017CQ4 2016Dec 31, 2016$301.63K–
Q4 FY2016CQ3 2016Sep 30, 2016$2.82M–
Q3 FY2016CQ2 2016Jun 30, 2016$752.45K–
Q2 FY2016CQ1 2016Mar 31, 2016$760.01K–

More Outlook Therapeutics figures

See a number that looks wrong?